- Shares of GTx (GTXI +9%) are trading notably higher.
- The company said today it will present top line results from POWER1 and POWER2 at the European Cancer Congress.
- The Phase 3 trials evaluated enobosarm as a treatment for muscle wasting in patients with non-small cell lung cancer.
- It's perhaps worth noting here that these trials did not meet their pre-specified criteria, news that, when released back on August 19, sent GTXI tumbling some 65%.
GTx rallies as company set to present data from trial misses at conference
Sep 24 2013, 11:06 ET